发明名称 Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
摘要 This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT4 receptor or of a functionally equivalent receptor.
申请公布号 US9168250(B2) 申请公布日期 2015.10.27
申请号 US201313855806 申请日期 2013.04.03
申请人 Centre National de la Recherche Scientifique-CNRS 发明人 Compan Valerie
分类号 A61K31/454;A61K31/445;C07K14/705;A61K38/00 主分类号 A61K31/454
代理机构 Oblon, McClelland, Maier & Neustadt, L.L.P. 代理人 Oblon, McClelland, Maier & Neustadt, L.L.P.
主权项 1. A method of treating a pathology associated with an obsessional behavior of a mammal in need thereof, wherein the pathology is anorexia, the method comprising administering a therapeutically effective amount of an antagonist of a 5-HT4 receptor, an inverse agonist of a 5-HT4 receptor, a pharmaceutically acceptable salt of the antagonist, or a pharmaceutically acceptable salt of the inverse agonist to the mammal to treat the mammal.
地址 Paris FR